Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Adecatumumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Adecatumumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Adecatumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Adecatumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Adecatumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Adecatumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Adecatumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Adecatumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Adecatumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Adecatumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Adecatumumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Adecatumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Adecatumumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Adecatumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Adecatumumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Adecatumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Adecatumumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Adecatumumab. |
| Equol | Equol may increase the thrombogenic activities of Adecatumumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Adecatumumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Adecatumumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Adecatumumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Adecatumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Adecatumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Adecatumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Adecatumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Adecatumumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Adecatumumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Adecatumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Adecatumumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Adecatumumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adecatumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Adecatumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Adecatumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Adecatumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Adecatumumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Adecatumumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Adecatumumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Adecatumumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Adecatumumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Adecatumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Adecatumumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Adecatumumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Adecatumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Adecatumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Adecatumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Adecatumumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Adecatumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Adecatumumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Adecatumumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Adecatumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Adecatumumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Adecatumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Adecatumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Adecatumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Adecatumumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Adecatumumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Adecatumumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Adecatumumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Adecatumumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Adecatumumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Adecatumumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Adecatumumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Canakinumab. |